Crossmark

SGLT2 inhibitors might halt progression of diabetic nephropathy

Crossref DOI link: https://doi.org/10.1038/nrneph.2016.109

Published Online: 2016-07-18

Published Print: 2016-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yamout, Hala

Bakris, George L.
License Information

Text and Data Mining valid from 2016-07-18
More Information

Article History

First Online: 18 July 2016

Competing interests

: G.L.B. has consulted for Bayer, Boehringer-Ingelheim, Takeda, AbbVie, Janssen, Merck, Astra-Zeneca and Relypsa. H.Y. declares no competing interests.